Coronary disease & ACS

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated with percutaneous coronary intervention. -insights from the SWEDEHEART registry

Am Heart JPublished registry study

Authors' conclusion

In patients with AF undergoing PCI for ACS, the use of oral anticoagulants increased over time. Both a VKA- and DOAC-based strategy were associated with lower MACE and NACE, with no significant difference between the two strategies.

Study context

Population
Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) undergoing PCI between 2010 and 202229% women, median age 76 years
Participants
15,358 patients
Exposure
Vitamin K antagonist (VKA)-based and direct oral anticoagulant (DOAC)-based strategies compared with platelet inhibition (PI) only
  • VKA-basedn = 4,155
  • DOAC-basedn = 4,962
  • PI onlyn = 6,241reference
Outcome
Proportion treated with oral anticoagulants
Follow-up
2010 to 2021
Methodological detailsSWEDEHEART registry, Cox regression adjusted for baseline characteristics
  • SWEDEHEART registry
  • Cox regression adjusted for baseline characteristics

Main finding

As reported in the abstract

Proportion treated with oral anticoagulants

2010

27%

2021

82%

Observational data: associations, not effects.

Further findings

OutcomeaHR (95% CI)
MACE (all-cause death, MI, or stroke)VKA-basedvs PI onlyAdjusted Cox regression0.80 (0.73–0.89)
MACE (all-cause death, MI, or stroke)DOAC-basedvs PI onlyAdjusted Cox regression0.82 (0.74–0.90)
NACE (MACE or major bleeding)VKA-basedvs PI onlyAdjusted Cox regression0.86 (0.78–0.94)
NACE (MACE or major bleeding)DOAC-basedvs PI onlyAdjusted Cox regression0.85 (0.77–0.93)

Major adverse cardiovascular events (MACE) (all-cause death, myocardial infarction (MI), or stroke)

No difference between the two OAC strategies

Net adverse cardiovascular event (NACE) (MACE or major bleeding)

No difference between the two OAC strategies

Original publication

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome treated with percutaneous coronary intervention. -insights from the SWEDEHEART registry. Am Heart J. Published 17 November 2026. doi:10.1016/j.ahj.2026.107657

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.